China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor

Nicole DeFeudis

Editor

Nearly a year after Nanjing, China-based InxMed bagged its first-ever IND approval, the company has raked in ¥130 million (about $19 million) in a Series …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Chi­na biotech In­xMed bags $19M Se­ries A+ to de­vel­op PhI FAK in­hibitor

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor